Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.806 USD | -2.93% | -5.74% | +70.66% |
Mar. 05 | North American Morning Briefing : S&P 500 Futures -2- | DJ |
Jan. 22 | Alaunos Therapeutics, Inc. Appoints Dale Curtis Hogue, Jr. as Interim Chief Executive Officer | CI |
Financials (USD)
Sales 2023 * | 4K | Sales 2024 * | - | Capitalization | 29.78M |
---|---|---|---|---|---|
Net income 2023 * | -35M | Net income 2024 * | -9M | EV / Sales 2023 * | 7,446 x |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.83
x | P/E ratio 2024 * |
-3.1
x | Employees | 34 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.6% |
Latest transcript on Alaunos Therapeutics, Inc.
1 day | -2.70% | ||
1 week | -5.74% | ||
Current month | -13.41% | ||
1 month | -22.99% | ||
3 months | +74.10% | ||
6 months | -8.04% | ||
Current year | +70.66% |
Managers | Title | Age | Since |
---|---|---|---|
Dale Hogue
CEO | Chief Executive Officer | 54 | Dec. 28 |
Director of Finance/CFO | 62 | 21-02-16 | |
Chief Tech/Sci/R&D Officer | 44 | 22-08-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jaime Vieser
BRD | Director/Board Member | 54 | 20-12-15 |
Holger Weis
CHM | Chairman | 61 | 20-12-15 |
Robert Postma
BRD | Director/Board Member | 70 | 21-02-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1.806 | -2.93% | 67 960 |
24-03-27 | 1.86 | -1.59% | 24,730 |
24-03-26 | 1.89 | -1.05% | 27,835 |
24-03-25 | 1.91 | +2.69% | 59,691 |
24-03-22 | 1.86 | -3.12% | 61,788 |
Delayed Quote Nasdaq, March 28, 2024 at 03:52 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+70.66% | 29.78M | |
+2.77% | 108B | |
+9.78% | 104B | |
+6.58% | 23.66B | |
-12.49% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.50% | 16.19B | |
+4.61% | 13.72B | |
+35.22% | 12.22B |